The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.
The regulator's Pharmacovigilance Risk Assessment Committee, which monitors drugs' side effects, said that no updates were required to the treatments' product information after reviewing the available evidence.
Shares of Danish drugmaker Novo Nordisk rose nearly 2% after the EMA released its findings.
The finding comes after the European Medicines Agency (EMA) extended in December its review into the class of weight-loss and diabetes drugs known as GLP-1 receptor agonists, to get more data from drugmakers to further investigate the issue.
The analysis started in July after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm after using Novo's drugs. The review focused on medicines that contain either semaglutide or liraglutide, both GLP-1 targeting compounds.
Liraglutide is the active ingredient in Novo's weight-loss treatment Saxenda while semaglutide is the active ingredient in Wegovy and top-selling diabetes treatment Ozempic.
The EMA analysed results from a large US study and did not find a direct association between the use of semaglutide and suicidal thoughts.
Results from another study conducted by EMA also did not support a link between GLP-1 drugs and risk of suicidal thoughts. Both the studies were based on electronic health records.
The U.S. Food and Drug Administration's preliminary review in January also found no link between GP-1 drugs and suicidal thoughts or actions.
GLP-1 receptor agonists, originally developed to help control blood sugar in patients with diabetes in Novo's Nordisk's Ozempic and Mounjaro developed by Eli Lilly, also slow digestion and reduce hunger.
https://uk.finance.yahoo.com/news/eu-regulator-finds-no-between-101521443.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.